3496 results about "Pathogenesis" patented technology

The invention includes compositions, kits and methods comprising a monoclonal antibody which shares key functional properties with the polyclonal antibodies which participate in the pathogenesis of heparin induced thrombocytopenia / thrombosis (HIT / HITT) in a mammal. The monoclonal antibody of the invention preferentially binds with a PF4 / heparin complex relative to the binding of the antibody with PF4 or heparin alone. The monoclonal antibody of the invention also binds specifically with PF4 in a complex with other glycosaminoglycans besides heparin, and also activates platelets. The monoclonal antibody of the invention is useful in methods for diagnosing and treating HIT / HITT in a mammal. A humanized version of the monoclonal antibody of the invention is also included, along with a process for humanizing the monoclonal antibody of the invention.

Compounds of the formIn which Q is selected from —CH═NR12, —W, —CH2NHR13, —CH═O and —CH(OR17)2 capable of modulating the activity of histone demethylases (HDMEs), which are useful for prevention and / or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, such as e.g. cancer and formulations and methods of use of such compounds.

The present application discloses compounds capable of modulating the activity of histone demethylases (HDMEs), which are useful for prevention and / or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, such as e.g. cancer. The present application also discloses pharmaceutical compositions comprising said compounds and the use of such compounds as a medicament. The compounds take the form

The invention provides method, system and device for determining trabecular bone structure and strength by digital topological analysis, and offers, for the first time, a demonstration of superior associations between vertebral deformity and a number of architectural indices measured in the distal radius, thus permitting reliable and noninvasive detection and determination of the pathogenesis of osteoporosis. A preferred embodiment provides imaging in three dimension of a region of trabecular bone, after which the 3D image is converted into a skeletonized surface representation. Digital topological analysis is applied to the converted image, and each image voxel is identified and classified as a curve, a surface, or a junction; and then associated with microarchitectural indices of trabecular bone to quantitatively characterize the trabecular bone network. The invention is applicable in vivo, particularly on human subjects, or ex vivo.

Disclosed herein are sequences, molecules and methods used to suppress the expression of HD genes encoding for huntingtin protein in primates including Macaca mulatta and Homo sapiens. These sequences, molecules and methods aid in the study of the pathogenesis of HD and can also provide a treatment for this disease.

A human T cell clone recognizing an antigen expressed by a synovial cell of a rheumatoid arthritis (RA) patient in HLA-DR-restricted manner is disclosed, which clone is very useful in exploring the pathogenesis of RA and developing a method for treating and preventing RA.

The invention provides methods for decreasing or inhibiting human immunodeficiency virus (HIV) infection or pathogenesis (e.g., illness) of a cell in vitro, ex vivo or in vivo, a symptom or pathology associated with human immunodeficiency virus (HIV) infection or pathogenesis (e.g., illness) in vitro, ex vivo or in vivo, or an adverse side effect of human immunodeficiency virus (HIV) infection or pathogenesis (e.g., illness) in vitro, ex vivo or in vivo. In one embodiment, a method of the invention includes treating a subject with an invention compound (e.g., cationic steroid antimicrobial or CSA).

Fish derived serine proteinases including trypsins and chymotrypsin derived from cod such as Atlantic cod is used for treating and / or preventing a variety of diseases and disorders such as inflammatory diseases, infectious diseases caused by viruses, bacteria and fungal species and diseases where a receptor binding mechanism is involved in the pathogenesis. Pharmaceutical and cosmetic compositions comprising the proteinases are described.

The invention relates to novel ligands of 5-HT6 receptor, to a pharmaceutical composition containing said novel ligands of 5-HT6 receptor as active component and to novel medicaments used for humans and warm-blooded animals for treating diseases and conditions of central nervous system, in pathogenesis of which neuromediator systems induced by 5-HT6 receptors are playing an essential role.Azaheterocyclic compounds of the general formula 1 or racemates, or optical or geometrical isomers, or pharmaceutically acceptable salts and / or hydrates thereof are used as 5-HT6 ligands.Wherein R2 and R3 independently of each other represent an amino group substituent selected from hydrogen; substituted carbonyl; substituted aminocarbonyl; substituted aminothiocarbonyl; substituted sulphonyl; C1-C5-alkyl optionally substituted by: C6-C10-arylaminocarbonyl, heterocyclyl, C6-C10-arylaminocarbonyl, C6-C10-arylaminothiocarbonyl, C5-C10-azaheteroaryl, optionally substituted carboxyl, nitryl group, optionally substituted aryl; R1k represents from 1 to 3 substituents of cyclic system, independent of each other and selected from hydrogen, optionally substituted C1-C5-alkyl, C1-C5-alkoxy, C1-C5-alkenyl, C1-C5-alkynyl, halogen, trifluoromethyl, CN-group, carboxyl, optionally substituted aryl, optionally substituted heterocyclyl, substituted sulfonyl, optionally substituted carboxyl; the solid line accompanied by the dotted line represents a single or a double bond; n=1, 2 or 3.

The invention relates to a Chinese medicine for treating psoriasis, in particular to Chinese medicinal powder for treating psoriasis. The Chinese medicinal powder for treating psoriasis consists of Chinese medicinal powder for oral administration and external embrocation, wherein the Chinese medicinal powder for oral administration consists of 45 Chinese medicines of angelica dahurica, cicada slough and the like; and the external embrocation consists of 18 Chinese medicines of centipede, scorpion and the like and medicinal ethanol and dimethyl sulfoxide. In the Chinese medicinal powder for treating psoriasis, on the basis of a secret recipe handed down in the family, the pathogenesis of psoriasis is found, and Chinese medicinal decoction tablets which are beneficial for clearing heat, cooling blood and detoxicating, dispelling wind, arresting itching and detoxicating, removing dampness, promoting blood circulation and detoxicating, enriching blood, moistening dryness and detoxicating or Chinese medicinal decoction tablets of insects medicines for detoxicating and eliminating toxic materials and the like are subjected to compatibility scientifically by many years of clinical experiences, and medicines for oral administration and external use are prepared by the conventional process; and due to the adoption of the conventional preparation technology, the Chinese medicinal powder for treating psoriasis is a pure Chinese medicinal preparation, has the characteristics of addressing both symptoms and root causes along with no toxic or side effect, relapse prevention and the like, is convenient to use, economic and practical, and patients can use safely and have light burden.

The present invention relates to the field of medical treatments for diseases and disorders. More specifically, the present invention relates to the use of the lanthionine synthetase component C-like (LANCL) proteins as therapeutic targets for novel classes of anti-inflammatory, immune regulatory and antidiabetic drugs. This includes but it is not limited to abscisic acid (ABA), ABA analogs, benzimidazophenyls, repurposed drugs or drug combinations, including thiazolidinediones (TZDs); naturally occurring compounds such as conjugated diene fatty acids, conjugated triene fatty acids, isoprenoids, and natural and synthetic agonists of peroxisome proliferator-activated receptors that activate this receptor through an alternative mechanism of action involving LANCL2 or other membrane proteins to treat or prevent the common inflammatory pathogenesis underlying type 2 diabetes, atherosclerosis, cancer, some inflammatory infectious diseases such as influenza and autoimmune diseases including but not limited to inflammatory bowel disease (Crohn's disease and Ulcerative colitis), rheumatoid arthritis, multiple sclerosis and type 1 diabetes and other chronic inflammatory conditions.

The present invention provides materials and methods to treat immune disease in which cytokines are involved in pathogenesis. The materials and methods of the present invention are useful in the treatment of autoimmune diseases. The materials and methods of the present invention are directed to nucleic acid ligands capable of binding to human IL-23 and / or human IL-12 cytokines and thus modulate their biological activity and are useful as therapeutic agents in immune, auto-immune and cancer therapeutics.

The invention relates to an animal behaviour testing platform for optogenetics regulation and control, used for carrying out a behaviour test on tested animals. The testing platform comprises a central control system, an environmental control system, a behaviour monitoring system, a photoelectric detection, regulation and control system and a case device used for fixing the systems. A standard and integrated behaviour testing platform used for testing animal optogenetics regulation and control is established by combining an optogenetics neural regulation and control technology and electrophysiology and behaviour tests and the like; by virtue of the platform, optogenetics regulation and control as well as behaviour record on the tested animals in certain environment can be realized, thus being easy to understand relation between the animal optogenetics regulation and control and the behaviour and meeting requirements of research on pathogenesis and treatment mechanism of a nervous system and mental diseases.

Provided are methods for determining concurrently with a simple, minimally invasive test, the adequacy of pancreatic beta-cell compensation and / or the presence of tissue insulin resistance in a subject human or an experimental animal. The methods allow for the determination of a subject's or experimental animal's susceptibility to developing type 2 diabetes mellitus (DM2) or to progression to more advanced forms of DM2. Among other uses, the methods allow for diagnostic classification of subjects for decisions regarding therapeutic interventions, clinical differentiation between type 1 DM and DM2, clinical monitoring of treatments intended to reduce risk of developing DM2 in non-diabetic subjects, clinical monitoring of agents intended to improve existing DM2 and to prevent progression of DM2, clinical development and testing of new compounds, candidate agents, or candidate therapies for preventing progression to DM2 or disease progression in existing DM2, and preclinical screening of candidate agents or candidate therapies in experimental animals to identify and characterize agents having insulin-sensitizing properties, pancreatic stimulatory or regenerative properties or other desirable actions.

The invention provides methods for decreasing or inhibiting herpesviridae (HV) infection or pathogenesis of a cell in vitro, ex vivo or in vivo, a symptom or pathology associated with a herpesviridae (HV) infection or pathogenesis in vitro, ex vivo or in vivo, or an adverse side effect of herpesviridae (HV) infection or pathogenesis in vitro, ex vivo or in vivo. In one embodiment, a method of the invention includes treating a subject with an invention compound (e.g., cationic steroid antimicrobial or CSA).

The invention discloses a manufacturing method and application of II type pig ring virus nucleic acid vaccine. The method is: 1) designs the specific primer, uses PCV2 Hangzhou (HZ201) gene group as template, closes ORF1, ORF2, ORF3 and ORF4 genes of PCV-2 with PCR method, and they are constructed into eucaryon expressing carrier with pCI-neo; 2) separates the pig external blood single nucleus cell, clones the genes IFN, IL-2 and IL-4 with RT-PCR method, and they are constructed into eucaryon expressing carrier with pCI-neo; 3) based on above mentioned reconstructed carrier, constructs the fused expressing carrier of the other genes of PCV2, ORF2 and PCV2 or pig cell factor gene; the merits of the invention lie in: (1) it needs not to culture virus, the producing period is short; (2) it needs not cell culture, thus can prevent the contamination from other pig source virus; (3) it does not express the pathogenesis protein which is harmful to body, the safety is high. (4) it can activates body secretion and cell immunity replay at the same time.

The invention provides methods for decreasing or inhibiting herpesviridae (HV) infection or pathogenesis of a cell in vitro, ex vivo or in vivo, a symptom or pathology associated with a herpesviridae (HV) infection or pathogenesis in vitro, ex vivo or in vivo, or an adverse side effect of herpesviridae (HV) infection or pathogenesis in vitro, ex vivo or in vivo. In one embodiment, a method of the invention includes treating a subject with an invention compound (e.g., cationic steroid antimicrobial or CSA).

This invention describes a bifidobacterium, i.e., bifidobacterium longum BM358 that can resist intestinal pathogens as well as resist oxidation. The bifidobacterium longum has such properties as high security, outstanding acid and bile resistance, adhesion to intestinal epithelial cells, outstanding intestinal pathogen resistance and oxidation resistance. The bifidobacterium longum can be used to prevent and treat gastritis, gastrelcosis and duodenitis caused by pylorus helicobacteria, and enteritis, acute diarrhea and enterogastric disorder caused by colibacillus and other intestinal pathogens.

The invention provides a gene knockout vector and a zebra fish glioma model thereof. The gene knockout vector is obtained by connecting a target sequence to plasmids capable of expressing CRISPR-Cas9gene editing system related enzymes, and the target gene is a p53, Rb1 or Nf1 gene. The CRISPR / CAS9 technology is utilized for performing targeted knockout of rb1, nf1 and tp53 genes, an established transgene-induced malignant glioma zebra fish model can observe occurrence of malignant gliomas, tumor-induced angiogenesis and glioma stem cell generating processes through real-time fluorescence, andthe difference of pathogenesis of gliomas under different genetic background conditions is studied through the molecular biotechnology.

The present invention relates to biomedicine technology, and is especially technological process of inducing and differentiating hemopoietic stem / ancestral cell of different sources into mature red blood cell by means of the support of stroma cell in a serum-free culture system. By means of the common culturing of stroma cell originated from embryo liver or mesenchyme stem cell originated from embryo marrow and erythron ancestral cell in different extracorporeal induction stages, the present invention realizes complete denucleation of erythrocyte to create erythrocyte with complete function. The present invention makes it possible to provide great amount of general or rare hematypic erythrocyte products for medical application.

The present invention discloses a cancer-related genes finding method by using miRNA expression data, based on a pan-cancer program PanCancer under The Cancer Genome Atlas (TCGA), and uses statistical analysis and a machine learning algorithm to carry out analysis and processing on the gene expression data, and to identify complex diseases related genes. The method comprises: sorting out sample data; carrying out statistical analysis on the miRNA expression data; sorting miRNA in order of an average change rate; selecting a target gene; extracting a corresponding disease sample and normal sample; and using a Relief algorithm to sort genes in the extracted miRNA sample. The method disclosed by the present invention can find a plurality of risk genes related to cancer and other complex diseases, and has important significance to a biological target therapy, biomedical research, pathogenesis explanation, risk prediction, and the like.

The invention discloses a magnetic resonance imaging (MRI) based brain disease individual prediction method and a magnetic resonance imaging (MRI) based brain disease individual prediction system. The method comprises the following steps: 1: obtaining the MRI of the brain of a patient with mental diseases; 2: carrying out denoising and dimension reduction treatment on the MRI of the brain of the patient; 3: carrying out feature selection by utilizing a ReliefF algorithm; 4: adaptively obtaining a spatial brain area by using a spatial cluster analysis method; 5: removing redundant features by utilizing a correlation-based feature selection algorithm, thus obtaining an optimal feature subset; 6: carrying out multiple linear regression analysis based on the optimal feature subset to recognize potential biomarkers. The method has the beneficial effects that the embodiment of the invention integrates various machine learning methods and can rapidly and conveniently achieve quantitative and individual accurate prediction of the interest features of mental diseases, such as clinical indexes, based on various image data in different mode types, thus being beneficial to understanding the brain structures, function abnormity and potential pathogenesis of the diseases.

The invention relates to a medical gasification resectoscope for inspecting and electric-cutting in urinary system. The opened operation of the traditional urinary system has the defects of large cut and damnifies, a plurality of blooding during operation and stimulated symptoms, long pathogenesis and enormous pains after the operation. The invention provides the gasification resectoscope, which comprises a main body, a sheath, an endotheca capable for inserting into the sheath and an inserting piece capable of inserting into the endotheca. The invention has the advantages of unnecessary of operating, small pain, light blooding, quick for recovery and reliable effects, which enables the operation safer, more precious and thorough, thus largely deducing the operation time, releasing the pain of the patients and shortening the curing time; besides, the invention is capable of being sterilized with high temperature and pressure and features uneasy for rusting; in addition, the physiological saline and excision enter and exit through different cannuls, thus enabling the cutting scope easy for control and has simple operation and clear version.

The invention relates to the molecular biology field and particularly relates to a gene knockout carrier, a construction method and application thereof and a gene knockout method of an NLRP1 gene of an MH7A cell. A CRISPR-Cas9 gene knockout system is utilized for carrying out CRISPR targeting sequence design by taking NLRP1 as a target gene so as to prepare a knockout carrier aiming at the NLRP1 gene, and the knockout carrier is utilized for transfecting the MH7A cell, so that the NLRP1 gene in the MH7A cell can be efficiently knocked out; and therefore, a research platform for rheumatoid arthritis is effectively built, so that the research of the pathogenesis of the rheumatoid arthritis is greatly promoted, and the researches of the interaction of NLRP1 inflammasomes and various inflammatory factors and the disease related molecular mechanisms of the rheumatoid arthritis and meningitis can be promoted.

The present invention provides a crystallized N-terminal domain of an NS5A protein of hepatitis C virus, methods of producing the same and methods of use thereof. The present invention also relates to structural elements of the N-terminal domain of hepatitis C virus NS5A protein, and methods of inhibiting hepatitis C virus infection, replication and / or pathogenesis, by interacting with the same.

In one embodiment, the invention provides a method of treating, reducing the incidence, reducing the severity or pathogenesis of an eye disease or disorder in a subject, including, inter alia, retinal detachment, macular degeneration, glaucoma or retinopathy, comprising the step of administering an effective amount of a lipid or phospholipid moiety bound optionally via a spacer to a physiologically acceptable monomer, dimer, oligomer, or polymer via an ester or amide bond, and / or a pharmaceutically acceptable salt or a pharmaceutical product thereof. This invention also provides a contact lens solution comprising a lipid or phospholipid moiety bound optionally via a spacer to a physiologically acceptable monomer, dimer, oligomer, or polymer via an ester or amide bond, and / or a pharmaceutically acceptable salt or a pharmaceutical product thereof.

The invention discloses glasses having dynamic slight defocusing and zooming functions in an emmetropia direction and an eyesight adjusting device, and belongs to the field of eyesight rehabilitation glasses. The glasses include a carrier, a dynamic slight defocusing and zooming device having dynamic slight defocusing and zooming functions and arranged on the carrier, and an automatic focusing device for driving the dynamic slight defocusing and zooming device to defocus and zoom; the dynamic slight defocusing and zooming device includes a zooming lens group away from eyeballs and replacement lenses close to the eyeballs. The glasses can induce the eye axis length of ametropia to gradually recover to an emmetropia eye axis state; the eyesight adjusting device makes a bionic vision training device fused with the emmetropia direction dynamic slight defocusing and zooming glasses. The glasses are suitable for eliminating pathogenesis generating myopia, hyperopia, astigmatism, anisometropia, strabismus and amblyopia, and are suitable for prevention and treatment of myopia, hyperopia, astigmatism, anisometropia, strabismus, amblyopia and visual fatigue.